Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 2016 May 4

PMID 27141054

Citations 15

Authors

Tram Anh Tran

Hon Sing Leong

Andrea Pavia-Jimenez

Slavic Fedyshyn

Juan Yang

Blanka Kucejova

Sharanya Sivanand

Patrick Spence

Xian-Jin Xie

Samuel Pena-Llopis

Nicholas Power

James Brugarolas

Affiliations

Soon will be listed here.

Abstract

Antiangiogenic therapies, such as sunitinib, have revolutionized renal cell carcinoma (RCC) treatment. However, a precarious understanding of how resistance emerges and a lack of tractable experimental systems hinder progress. We evaluated the potential of primary RCC cultures (derived from tumors and tumor grafts) to signal to endothelial cells (EC) and fibroblasts in vitro and to stimulate angiogenesis ex vivo in chorioallantoic membrane (CAM) assays. From 65 patients, 27 primary cultures, including several from patients with sunitinib-resistant RCC, were established. RCC cells supported EC survival in coculture assays and induced angiogenesis in CAM assays. RCC-induced EC survival was sensitive to sunitinib in half of the tumors and was refractory in tumors from resistant patients. Sunitinib sensitivity correlated with vascular endothelial growth factor (VEGF) production. RCC induced paracrine extracellular signal-regulated kinase (ERK) activation in EC which was inhibited by sunitinib in sensitive but not in resistant tumors. As determined by fibroblast growth factor receptor substrate 2 (FRS2) phosphorylation in fibroblasts, RCC broadly induced low-level fibroblast growth factor receptor (FGFR) signaling. Whereas ERK activation in EC was uniformly inhibited by combined VEGF/platelet-derived growth factor (PDGF)/FGF receptor inhibitors, paracrine ERK activation in fibroblasts was blocked in only a fraction of tumors. Our data show that RCC activates EC through VEGF-dependent and -independent pathways, that sunitinib sensitivity correlates with VEGF-mediated ERK activation, and that combined inhibition of VEGF/PDGF/FGF receptors is sufficient to inhibit mitogenic signaling in EC but not in fibroblasts.

Citing Articles

Hsa_circ_0072732 enhances sunitinib resistance of renal cell carcinoma by inhibiting ferroptosis.

Tian X, Liu J, Yi C, You X, Yuan C Discov Oncol. 2024; 15(1):700.

PMID: 39580569 PMC: 11585529. DOI: 10.1007/s12672-024-01580-2.

Curcumin Inhibits Proliferation of Renal Cell Carcinoma in vitro and in vivo by Regulating miR-148/ADAMTS18 through Suppressing Autophagy.

Xu B, Yuan C, Zhang J Chin J Integr Med. 2022; 29(8):699-706.

PMID: 36477451 DOI: 10.1007/s11655-022-3690-9.

Advances in Renal Cell Carcinoma Drug Resistance Models.

Xiang Y, Zheng G, Zhong J, Sheng J, Qin H Front Oncol. 2022; 12:870396.

PMID: 35619895 PMC: 9128023. DOI: 10.3389/fonc.2022.870396.

Multi-Omics Investigations Revealed Underlying Molecular Mechanisms Associated With Tumor Stiffness and Identified Sunitinib as a Potential Therapy for Reducing Stiffness in Pituitary Adenomas.

Wang Z, Chang M, Zhang Y, Zhou G, Liu P, Lou J Front Cell Dev Biol. 2022; 10:820562.

PMID: 35372359 PMC: 8965615. DOI: 10.3389/fcell.2022.820562.

Microphysiological model of renal cell carcinoma to inform anti-angiogenic therapy.

Virumbrales-Munoz M, Ayuso J, Loken J, Denecke K, Rehman S, Skala M Biomaterials. 2022; 283:121454.

PMID: 35299086 PMC: 9254636. DOI: 10.1016/j.biomaterials.2022.121454.

References

Shen S, Truong L, Scarpelli M, Lopez-Beltran A . Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful?. Arch Pathol Lab Med. 2012; 136(4):410-7. DOI: 10.5858/arpa.2011-0472-RA. View

Casanovas O, Hicklin D, Bergers G, Hanahan D . Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8(4):299-309. DOI: 10.1016/j.ccr.2005.09.005. View

Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N . Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2005; 24(1):25-35. DOI: 10.1200/JCO.2005.02.2194. View

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

Ribatti D, Nico B, Vacca A, Presta M . The gelatin sponge-chorioallantoic membrane assay. Nat Protoc. 2007; 1(1):85-91. DOI: 10.1038/nprot.2006.13. View

Huang D, Ding Y, Li Y, Luo W, Zhang Z, Snider J . Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 2010; 70(3):1053-62. DOI: 10.1158/0008-5472.CAN-09-3722. View

Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J . Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor.... J Med Chem. 2003; 46(7):1116-9. DOI: 10.1021/jm0204183. View

Cockman M, Masson N, Mole D, Jaakkola P, Chang G, Clifford S . Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2000; 275(33):25733-41. DOI: 10.1074/jbc.M002740200. View

Faivre S, Demetri G, Sargent W, Raymond E . Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007; 6(9):734-45. DOI: 10.1038/nrd2380. View

10.

Motzer R, Hutson T, Tomczak P, Michaelson M, Bukowski R, Rixe O . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2):115-24. DOI: 10.1056/NEJMoa065044. View

11.

Gerber H, McMurtrey A, Kowalski J, Yan M, Keyt B, Dixit V . Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998; 273(46):30336-43. DOI: 10.1074/jbc.273.46.30336. View

12.

Cenni E, Perut F, Granchi D, Avnet S, Amato I, Brandi M . Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma. Anticancer Res. 2007; 27(1A):315-9. View

13.

Shojaei F, Wu X, Malik A, Zhong C, Baldwin M, Schanz S . Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol. 2007; 25(8):911-20. DOI: 10.1038/nbt1323. View

14.

Ausprunk D, Knighton D, Folkman J . Vascularization of normal and neoplastic tissues grafted to the chick chorioallantois. Role of host and preexisting graft blood vessels. Am J Pathol. 1975; 79(3):597-618. PMC: 1913018. View

15.

Leong H, Chambers A, Lewis J . Assessing cancer cell migration and metastatic growth in vivo in the chick embryo using fluorescence intravital imaging. Methods Mol Biol. 2012; 872:1-14. DOI: 10.1007/978-1-61779-797-2_1. View

16.

Bender C, Ullrich A . PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines. Int J Cancer. 2011; 131(2):E45-55. DOI: 10.1002/ijc.26486. View

17.

Greenman C, Stephens P, Smith R, Dalgliesh G, Hunter C, Bignell G . Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446(7132):153-8. PMC: 2712719. DOI: 10.1038/nature05610. View

18.

Hadari Y, Gotoh N, Kouhara H, Lax I, Schlessinger J . Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. Proc Natl Acad Sci U S A. 2001; 98(15):8578-83. PMC: 37478. DOI: 10.1073/pnas.161259898. View

19.

Pan C, Chen P, Ho D . The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases. Histopathology. 2004; 45(5):452-9. DOI: 10.1111/j.1365-2559.2004.01962.x. View

20.

Shi W, Siemann D . Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor. Br J Cancer. 2002; 87(1):119-26. PMC: 2364273. DOI: 10.1038/sj.bjc.6600416. View